Arca
Skip to content
Tools
Tools

Nasal polyposis

Drug research and approvals for nasal polyposis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 42 studies of nasal polyposis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 13 drug trials for it since 2013.

  • Recruiting worldwide: 42
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 42 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 13; search them all in Canada trials
Feb 24, 2026A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic…Itepekimab (SAR440340)Sanofi-Aventis Canada IncClosed
Dec 5, 2024A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab)Sanofi-Aventis Canada IncOngoing
Dec 5, 2024A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab)Sanofi-Aventis Canada IncClosed
Nov 6, 2024A multicentre, single-arm, phase 3b study to assess changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating…TezepelumabAstraZeneca PharmaceuticalsOngoing
Apr 25, 2024A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab/LY3650150 in…Lebrikizumab (LY3650150)Eli LillyOngoing
Nov 13, 2020A multicentre, randomised, double-blind, parallel-group, placebo-controlled phase 3 efficacy and safety study of tezepelumab in participants with severe…Tezepelumab (MEDI9929/AMG 157)AstraZeneca PharmaceuticalsOngoing
Jun 30, 2020A multicentre, double-blind, parallel-group, placebo-controlled phase 3 efficacy and safety study of benralizumab for the prevention of recurrence of nasal…Benralizumab (MEDI-563)AstraZeneca PharmaceuticalsPending
Dec 5, 2018A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SOC) for assessment of the…Fevipiprant (QAW039)Novartis PharmaceuticalsOngoing
Mar 7, 2018Open-label extension study of omalizumab in patients with chronic rhinosinusitis with nasal polypsXolairRocheClosed
Dec 27, 2017A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 efficacy and safety study of benralizumab in patients with severe nasal…MEDI-563AstraZeneca PharmaceuticalsClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.